222 related articles for article (PubMed ID: 15685824)
1. Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.
Konecny GE; Pegram MD
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 12):32-6. PubMed ID: 15685824
[TBL] [Abstract][Full Text] [Related]
2. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Pegram MD; Konecny GE; O'Callaghan C; Beryt M; Pietras R; Slamon DJ
J Natl Cancer Inst; 2004 May; 96(10):739-49. PubMed ID: 15150302
[TBL] [Abstract][Full Text] [Related]
3. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
[TBL] [Abstract][Full Text] [Related]
4. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
Slamon D; Pegram M
Semin Oncol; 2001 Feb; 28(1 Suppl 3):13-9. PubMed ID: 11301370
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer overexpressing HER2/neu.
Stein S; DeMichele A; Domchek S; Fox K
Clin Breast Cancer; 2004 Jan; 4 Suppl 3():S117-20. PubMed ID: 14754469
[TBL] [Abstract][Full Text] [Related]
6. Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.
Oudard S; Culine S; Vano Y; Goldwasser F; Théodore C; Nguyen T; Voog E; Banu E; Vieillefond A; Priou F; Deplanque G; Gravis G; Ravaud A; Vannetzel JM; Machiels JP; Muracciole X; Pichon MF; Bay JO; Elaidi R; Teghom C; Radvanyi F; Beuzeboc P
Eur J Cancer; 2015 Jan; 51(1):45-54. PubMed ID: 25459391
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.
Gatzemeier U; Groth G; Butts C; Van Zandwijk N; Shepherd F; Ardizzoni A; Barton C; Ghahramani P; Hirsh V
Ann Oncol; 2004 Jan; 15(1):19-27. PubMed ID: 14679114
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer.
Loesch D; Asmar L; McIntyre K; Doane L; Monticelli M; Paul D; Vukelja S; Orlando M; Vaughn LG; Zhan F; Boehm KA; O'Shaughnessy JA
Clin Breast Cancer; 2008 Apr; 8(2):178-86. PubMed ID: 18621615
[TBL] [Abstract][Full Text] [Related]
9. High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study.
Stemmler HJ; Kahlert S; Brudler O; Beha M; Müller S; Stauch B; Heinemann V
Clin Oncol (R Coll Radiol); 2005 Dec; 17(8):630-5. PubMed ID: 16372489
[TBL] [Abstract][Full Text] [Related]
10. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
Sledge GW
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):33-5. PubMed ID: 14768403
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
13. New combinations with Herceptin in metastatic breast cancer.
Winer EP; Burstein HJ
Oncology; 2001; 61 Suppl 2():50-7. PubMed ID: 11694788
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.
Zinner RG; Glisson BS; Fossella FV; Pisters KM; Kies MS; Lee PM; Massarelli E; Sabloff B; Fritsche HA; Ro JY; Ordonez NG; Tran HT; Yang Y; Smith TL; Mass RD; Herbst RS
Lung Cancer; 2004 Apr; 44(1):99-110. PubMed ID: 15013588
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma.
Ropero S; Menéndez JA; Vázquez-Martín A; Montero S; Cortés-Funes H; Colomer R
Breast Cancer Res Treat; 2004 Jul; 86(2):125-37. PubMed ID: 15319565
[TBL] [Abstract][Full Text] [Related]
16. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
Pegram MD; Pienkowski T; Northfelt DW; Eiermann W; Patel R; Fumoleau P; Quan E; Crown J; Toppmeyer D; Smylie M; Riva A; Blitz S; Press MF; Reese D; Lindsay MA; Slamon DJ
J Natl Cancer Inst; 2004 May; 96(10):759-69. PubMed ID: 15150304
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine and trastuzumab in metastatic breast cancer.
O'shaughnessy J
Semin Oncol; 2003 Apr; 30(2 Suppl 3):22-6. PubMed ID: 12722022
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
Menendez JA; Mehmi I; Lupu R
J Clin Oncol; 2006 Aug; 24(23):3735-46. PubMed ID: 16847284
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer.
Yardley DA; Burris HA; Simons L; Spigel DR; Greco FA; Barton JH; Shipley D; Drosick D; Hainsworth JD
Clin Breast Cancer; 2008 Oct; 8(5):425-31. PubMed ID: 18952556
[TBL] [Abstract][Full Text] [Related]
20. Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer.
Yardley DA; Burris HA; Hanson S; Greco FA; Spigel DR; Barton J; Hainsworth JD
Clin Breast Cancer; 2009 Aug; 9(3):178-83. PubMed ID: 19661042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]